MORNING SESSION : 11 AM
Decision Point: China vs US and the Competitive Reality of Global Biopharma
China has spent two decades building a biotechnology ecosystem designed to challenge the United States and dominate on a global stage, moving from “me too” medicines to cutting edge innovation. China’s shift upstream to novel drug discovery and development, combined with shifting dynamics on the global geopolitical stage, presents new risks to the future of US biotech leadership. Meanwhile U.S. reliance on China for key medicines and materials, partnerships and in-licensing activity signal a rapidly shifting competitive landscape.
Will the US shape the future of biotechnology or be beholden to one defined by others? This private roundtable will examine the current state of U.S.–China strategic competition in biotechnology, where the status quo leads, and what must change now for the U.S. to sustain its leadership in biotechnology and the future of medicine.
LUNCH: 12:15 PM
AFTERNOON SESSIONS: 1:15 PM - 4:00 PM
America’s Innovation Engine: Advancing Cures
Scientific breakthroughs in biotechnology and artificial intelligence are accelerating the pace of drug development. As innovation races ahead, the critical question becomes whether the system guiding new therapies to patients can evolve just as quickly – without compromising trust or safety. This forward-looking session brings together leading voices from FDA and biotech to explore the art of the possible to ensure America’s innovation engine is running at full speed. This session will explore how regulatory advances, emerging technologies, and new development models can shorten the path from discovery to patients and what transformational change could mean for companies, capital formation, and the future of biotech innovation.
Healthcare on the Ballot: What’s at Stake in the Midterms
With healthcare costs rising, regulatory policy in flux, and public trust in experts and institutions under pressure, healthcare is poised to shape the political landscape heading into the 2026 midterm elections. For industry leaders, the stakes are unusually high: decisions made in Washington over the next year could reshape insurance markets, drug pricing policy, FDA oversight, vaccine access, and the future pace of medical innovation.
This fireside conversation will examine which healthcare issues are most likely to influence voters and policymakers in an intensely polarized environment, where control of Congress may hinge on a narrow band of independent voters. Panelists will unpack how campaign narratives, economic pressures, and evolving Administration priorities could translate into policy outcomes affecting patients, providers, payers, and innovators alike. This session will provide candid insight into the political crosscurrents shaping the industry—and what leaders should anticipate as election dynamics collide with urgent healthcare challenges.
Networking Cocktail Reception: 4:00 PM - 5:30 PM
)
)
)
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
